Published summary: 2026-03-07
Where the evidence converges
Meta-analysis of 18,000+ paired samples found oral fluid THC tests detect recent cannabis use well but are unreliable for predicting whether blood THC exceeds legal driving limits
Strong evidence · 10 studies
Paired samples came from various study conditions (controlled dosing, roadside testing, clinical). The relationship between blood THC and actual driving impairment is itself imperfect. Different oral
Largest-ever meta-analysis (183M patients) found cannabis use significantly associated with stroke risk but not heart attack risk — though observational data can't prove causation
Strong evidence · 10 studies
All included studies were observational — the association between cannabis and stroke cannot be confirmed as causal. Residual confounding is a major concern: cannabis users may differ from non-users i
First meta-analysis of CBD prevalence found nearly 29% lifetime use in North America vs
Strong evidence · 10 studies
High heterogeneity across studies. Wide confidence intervals for some estimates. Different CBD products and legal definitions across countries. Studies span different years and regulatory environments
Where questions remain
A historical review traced how federal laws, patient reports, and 25 state research acts moved THC from prohibition into active medical investigation by 1981
Moderate evidence · 127 studies
As a historical review focused on the U.S. regulatory landscape, it does not evaluate clinical evidence directly. The 25-state comparison covers legal frameworks, not research outcomes.
A 1998 review called for removing research barriers to medical marijuana while noting the narrow therapeutic window as a major limitation, supporting pharmaceutical-grade cannabinoid development
Moderate evidence · 127 studies
A single author's perspective rather than a systematic review. The characterization of evidence as "weak" may have been overstated for some conditions. The focus on pharmaceutical approaches may have
A pharmaceutical review found marijuana causes dependence but has less addictive power than cocaine, alcohol, heroin, or nicotine, and shows therapeutic promise for six conditions
Moderate evidence · 127 studies
A single-author review without systematic methodology. The characterization of cognitive impairments as "subtle" may understate effects found in subsequent research. The comparison of addiction potent
An ethics review applied the principle of double effect to IOM evidence and concluded that denying medical marijuana to seriously ill patients violates their dignity and right to effective therapy
Moderate evidence · 127 studies
The ethical analysis assumed the IOM evidence was definitive, though some of the evidence was preliminary. The principle of double effect, while established in ethics, involves subjective judgments ab
Research gaps
- Only 15 randomized controlled trials exist out of 647 studies — most evidence is observational or from reviews.
- Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
- Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.
Key studies
Nearly 29% of North Americans have tried CBD, about double the rate in Europe
Despite the explosive growth of the CBD market, no prior systematic assessment of how many people actually use CBD existed. These numbers provide a baseline for tracking trends as regulations and products evolve.
Cannabis and Heart Attack/Stroke Risk: A 183-Million-Patient Meta-Analysis Finds Stroke Risk but Not Heart Attack Risk
This is the largest meta-analysis of cannabis and cardiovascular risk ever conducted. With over 183 million patients, it has statistical power that individual studies lack. The finding that stroke risk is elevated while heart attack risk is not suggests cannabis may affect the cardiovascular system
Roadside Oral Fluid THC Tests Are Good at Detecting Any Cannabis Use but Poor at Predicting Blood Levels
Many countries use roadside oral fluid tests to enforce cannabis-impaired driving laws. This study shows these tests are useful for identifying recent cannabis use but unreliable for determining whether drivers exceed legal blood THC limits, with major implications for enforcement fairness.
Cannabis Advertising Was Associated With 77% Higher Odds of Cannabis Use
As cannabis markets expand advertising, understanding the use-advertising relationship is critical for regulation.
First Randomized Trial Comparing Legal and Illegal Cannabis Markets
This is the first randomized controlled trial directly comparing legal and illegal cannabis market effects on health outcomes. While observational studies of legalization exist, experimental evidence has been lacking.
Plain cannabis packaging improved health warning recall and reduced product appeal among young adults
Cannabis packaging regulations vary widely across legalized states. This study provides evidence that specific packaging features, particularly plain packaging and the absence of health claims, meaningfully affect how young adults perceive cannabis products and process safety warnings.
How the research developed
Pre-2000
5 studies published. Predominantly observational and review studies.
2000–2009
8 studies published. Includes 1 strong-evidence studies.
2010–2014
11 studies published. Predominantly observational and review studies.
2015–2019
97 studies published. Includes 3 RCTs, 16 strong-evidence studies.
2020–present
526 studies published. Includes 5 meta-analyses, 12 RCTs, 124 strong-evidence studies.
How this summary was assembled
This consensus synthesizes 647 peer-reviewed studies: 5 meta-analyses (1%), 15 randomized controlled trials (2%), 311 observational studies (48%), 91 reviews (14%), 1 case studies (0%), 224 other study types (35%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
These counts describe the source summary at publication. They may differ from the current library.